Vietnam's growing investment in laboratory diagnostics, preventive healthcare and chronic-disease management is creating new opportunities for urinalysis technologies across hospitals, clinical laboratories and point-of-care settings.
While publicly available research does not disclose a definitive Vietnam-specific market valuation, analysis of the country's diagnostics sector and international urinalysis market suggests that the Vietnam Urinalysis Market could be worth approximately US$25–35 million in 2025 and reach US$40–55 million by 2030.
Urinalysis is one of the most established forms of laboratory testing and provides clinicians with a rapid and comparatively low-cost method of detecting and monitoring a wide range of health conditions.
The market encompasses urine analysers, automated sediment analysers, test strips, reagents, consumables and associated laboratory technologies, serving hospitals, clinical laboratories, home healthcare, research and academic facilities. Vietnam-specific market research identifies both instruments and consumables as major product categories.
Chronic disease drives testing demand
One of the most important growth drivers is the increasing burden of chronic disease.
Urinalysis can provide valuable information in the diagnosis and monitoring of conditions including diabetes, kidney disease, hypertension, liver disease and urinary tract infections.
6Wresearch specifically identifies the increasing prevalence of chronic diseases in Vietnam as a driver of demand for urinalysis testing. Growing awareness of preventive healthcare and routine health screening is also encouraging greater use of diagnostic tests.
This makes urinalysis particularly relevant as Vietnam's healthcare system increasingly shifts towards earlier detection and long-term management of non-communicable diseases.
Automation transforms the laboratory
The technology behind urinalysis is also evolving.
Traditional urine analysis can involve manual dipstick interpretation and microscopic examination of urine sediment. Increasingly, laboratories are adopting automated biochemical and urine-sediment analysers capable of processing larger numbers of samples with greater consistency.
Globally, instruments are expected to be the fastest-growing product segment of the urinalysis market through 2030.
Automated systems can potentially improve laboratory throughput, standardise results and reduce dependence on manual microscopy—particularly valuable for high-volume hospital and diagnostic laboratories.
Consumables create a substantial recurring market
Although sophisticated instruments attract much of the technological attention, consumables represent the largest part of the global market.
Grand View Research reports that urinalysis consumables generated US$3.69 billion globally in 2024, representing the substantial majority of the US$4.37 billion overall market.
This includes products such as urine test strips, reagents, controls and other disposables, which generate recurring demand every time testing is performed.
For suppliers entering Vietnam, this makes the commercial opportunity significantly broader than the sale of analysers alone.
Point-of-care testing creates new opportunities
Urinalysis is also well suited to the movement of diagnostics closer to the patient.
Simple urine dipsticks can provide rapid results without sophisticated laboratory infrastructure, while compact automated analysers increasingly allow more advanced testing to be conducted in smaller healthcare facilities.
The wider international market is seeing increased adoption of point-of-care solutions, automation and digital diagnostics, which Research and Markets identifies among the factors supporting global urinalysis growth.
For Vietnam, point-of-care technologies could be particularly valuable in extending diagnostic capabilities beyond major urban hospitals.
Digital technologies improve interpretation
Digitalisation is also beginning to change urinalysis.
Modern analysers can connect directly with Laboratory Information Systems (LIS), automatically transferring results into patient records and reducing manual data entry.
Advanced urine-sediment systems can combine digital imaging with automated particle recognition, while AI-based image-analysis technologies have the potential to assist with classification of cells, casts, crystals and other elements within urine samples.
The result is a gradual transition from largely manual urinalysis towards a connected and increasingly automated diagnostic workflow.
Global market approaches US$7 billion
The international market provides a strong indication of the wider growth trajectory.
Grand View Research values the global Urinalysis Market at US$4.37 billion in 2024 and forecasts it to reach US$6.85 billion by 2030, representing a 7.8% CAGR between 2025 and 2030. Increasing incidence of urinary tract infections, diabetes and kidney disease are identified as important growth factors.
Research and Markets provides a similar outlook, estimating a US$4.34 billion global market in 2025, increasing to US$6.29 billion by 2030, at approximately 7.7% CAGR. It highlights digital and molecular diagnostics, automation, early disease detection and decentralised testing as important trends.
Vietnam's opportunity extends across the laboratory ecosystem
For diagnostic technology companies, the opportunity therefore extends across automated analysers, urine sediment systems, test strips, reagents, controls, digital microscopy, point-of-care diagnostics, laboratory automation and LIS connectivity.
6Wresearch's dedicated Vietnam study confirms an established market spanning hospitals, clinical laboratories, home healthcare, research and academic users, with forecasts extending through 2031.
As Vietnam continues to invest in laboratory infrastructure and expand preventive and chronic-disease diagnostics, urinalysis should remain an important component of routine clinical testing.
For IVD manufacturers, laboratory equipment companies, reagent suppliers and diagnostic technology providers, Vietnam therefore represents a developing market where the combination of rising test volumes, laboratory automation and point-of-care diagnostics is creating long-term commercial opportunities.